Find information on thousands of medical conditions and prescription drugs.

Zoladex

Goserelin is an injectable gonadotropin releasing hormone agonist (GnRH agonist). It stops the production of sex hormones (testosterone and oestrogen) and is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

It is available as a 1-month depot and a long-acting 3-month depot. Both depots are used for the treatment of prostate cancer, endometriosis and uterine fibroids but only the 1-month depot is approved for breast cancer, endometrial thinning and assisted reproduction.

Goserelin is marketed by AstraZeneca with the brand name Zoladex. It was first launched in 1987 and is currently the second-largest selling LHRHa in the world. It is currently available in more than one hundred markets.

Read more at Wikipedia.org


[List your site here Free!]


Research and Markets: the Endometriosis Market is Expected to Change Dramatically Following the Patent Expiry of Key Brands Lupron Depot, Zoladex and Suprefact
From Business Wire, 9/27/04

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of Pipeline Insight: Endometriosis - Growing the Patient Population is Key to Unlocking the Markets Commercial Potential to their offering

The current endometriosis market is underdeveloped, due to poor disease awareness and both low presentation and diagnosis rates.

Current therapies are limited in terms of efficacy and often have unwanted side effects.

This report gives an analysis of the endometriosis market, focusing on key R&D products for the disease and investigating existing treatment practices to highlight unmet needs.

Scope of Report:

--Epidemiology of endometriosis in seven major markets, identifying subpopulations and unmet needs

--Detailed profiles of drugs in Phase II and above examining clinical data and benchmarked against gold standard using quantitative SWOT analysis

--Country-specific sales forecasts for the seven major markets, based on IMS MIDAS data covering key ATC classes G3A, G3D, G3H, H1C1 (L2A) and H1C3

--Extensive secondary research and utilization of licensed and in-house databases supplemented by primary research interviews with key opinion leaders

Report Highlights:

The endometriosis market will change dramatically following the patent expiry of key brands Lupron Depot, Zoladex and Suprefact. This presents a challenge for R&D candidates, as pressure on pricing and genericization result in a greater demand for improvements over standard therapies in efficacy, tolerability, side effects and cost-effectiveness.

With an estimated symptomatic population of six million women, there is a significant latent potential. This is due to patients being lost in the treatment pathway through low presentation and diagnosis rates, compounded by poor disease awareness, as well as a lack of an effective, easily accessible, non-invasive diagnostic tool.

Although the pipeline is sparse, the unmet need in the market is such that We forecast combined sales of six late-stage R&D candidates of $2.2 bn by 2014. While GnRH antagonists are natural successors to Lupron and Zoladex, Schering AG/TAPs asoprisnil is expected to drive the pipeline and set the new standard in endometriosis treatment.

Reasons to Purchase:

--Quantify the future size and scope of the market, and the potential for new products

--Benchmark pipeline drugs against currently marketed products with drug profiles and SWOT analysis

--Measure the impact of key patent expiries using the forecasting model

For more information visit http://www.researchandmarkets.com/reports/c5460

COPYRIGHT 2004 Business Wire
COPYRIGHT 2004 Gale Group

Return to Zoladex
Home Contact Resources Exchange Links ebay